秋水仙碱与克拉霉素联用的临床意义药物相互作用证据
本研究通过FAERS数据库和文献检索分析秋水仙碱与克拉霉素联用的药物相互作用。FAERS发现58例报告,53%为65-85岁患者,30例死亡;文献20例中19例DIPS评级为「很可能」。毒性多在启用克拉霉素5天内出现,死亡在联用2周内。
要点
- 秋水仙碱与克拉霉素联用可致严重毒性,FAERS报告30例死亡。
- 毒性多在启用克拉霉素5天内出现,死亡在联用2周内。
- 临床表现包括腹泻、全血细胞减少、骨髓衰竭和呕吐。
核心结论
- 秋水仙碱与克拉霉素联用的临床表现可能类似其他系统性疾病,且可能危及生命。
- 理解这一具有临床意义的相互作用有助于临床医生避免不安全的药物组合。
研究设计与样本
- 通过FDA不良事件报告系统(FAERS)数据库检索秋水仙碱与克拉霉素联用的病例报告。
- 检索PubMed、EMBASE和Web of Science电子数据库(2005年1月至2019年11月)中报告两者联用的文章。
- 对个体报告进行审查,以确定联用后果、剂量、相互作用出现时间、症状、肾脏疾病证据、症状缓解时间和药物相互作用概率量表(DIPS)评级。
主要发现
- FAERS检索发现58例报告病例,其中近53%来自65至85岁患者。
- 30例报告死亡中,11例为男性,19例为女性。
- FAERS中报告的其他常见并发症包括腹泻(31%)、全血细胞减少(22%)、骨髓衰竭(14%)和呕吐(14%)。
- 从已发表文献中识别出20例联用暴露病例报告,其中19例根据DIPS评级为「很可能」,1例为「可能」。
- 这些病例中,4例「很可能」患者死亡;记录的秋水仙碱毒性在开始克拉霉素治疗后5天内出现,死亡在联用暴露后2周内发生。
临床怎么用
- 临床医生应认识到秋水仙碱与克拉霉素联用可能危及生命,避免不安全的药物组合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Colchicine is currently approved for the treatment of gout and familial Mediterranean fever, among other conditions. Clarithromycin, a strong inhibitor of CYP3A4 and P-glycoprotein, dramatically increases colchicine's half-life, augmenting the risk of a life-threatening adverse reaction when used inadvertently with colchicine. OBJECTIVES: The aim of this study was to examine the evidence and clinical implications of concomitant use of colchicine and clarithromycin. METHODS: Case reports of colchicine-clarithromycin co-administration were searched using the FDA's Adverse Event Reporting System (FAERS) database. PubMed, EMBASE, and Web of Science electronic databases were also searched from January 2005 through November 2019 for articles reporting colchicine-clarithromycin concomitant use. Individual reports were reviewed to identify consequences of coadministration, dose, days to onset of interaction, symptoms, evidence of renal disease, time to resolution of symptoms, and Drug Interaction Probability Scale (DIPS) rating. RESULTS: The FAERS search identified 58 reported cases, nearly 53% of which were from patients aged between 65 and 85 years. Of 30 reported deaths, 11 occurred in males, and 19 in females. Other frequent complications reported in FAERS included diarrhea (31%), pancytopenia (22%), bone marrow failure (14%), and vomiting (14%). From published literature, we identified 20 case reports of concomitant exposure, 19 of which were rated 'probable' and one 'possible' according to DIPS rating. Of these cases, four 'probable' patients expired. The documented onset of colchicine toxicity occurred within 5 days of starting clarithromycin, and death within 2 weeks of concomitant exposure. CONCLUSION: Clinical manifestations of colchicine-clarithromycin interaction may resemble other systemic diseases and may be life threatening. Understanding this clinically meaningful interaction can help clinicians avoid unsafe medication combinations.
引用
- Villa Zapata L, Hansten PD, Horn JR, et al. Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin. Drug Saf. 2020. PMID: 32274687. doi:10.1007/s40264-020-00930-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。